Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02163434 · ClinicalTrials.gov registry record · Phase 2
Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum
A Phase 2 study of Hyperemesis Gravidarum, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 2
- Study locations
NCT02163434: Completed Phase 2 study of Hyperemesis Gravidarum, sponsored by State University of New York at Buffalo.
NCT02163434 is a Phase 2 study of Hyperemesis Gravidarum that has completed, run by State University of New York at Buffalo. The registered enrollment target is 31 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02163434, a Phase 2 study of Hyperemesis Gravidarum, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators will compare the effectiveness of gabapentin to metoclopramide for 1 week among 60 women with hyperemesis gravidarum (HG) in this randomized, double-blinded trial. After completion of the 1-week double-blind phase, subjects will be offered open-label gabapentin with rescue metoclopramide until their symptoms no longer require treatment. Enrollment will occur at the University's at Buffalo, of Rochester and of Wisconsin.
Primary Outcome
Score range: 6-30 with higher score indicating a worse outcome.
Conditions Studied
Interventions
- DRUG Gabapentin
- DRUG Metoclopramide
Study Locations (2)
New York
- University at Buffalo - Buffalo
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-06 |
| Est. Completion | 2019-11 |
| Phase | Phase 2 |
What the finished NCT02163434 record still lists
NCT02163434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Hyperemesis Gravidarum appearing as the primary indexed condition, and to 2 interventions - of which Gabapentin is the first listed.
NCT02163434 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02163434 about?
NCT02163434 is a clinical study titled "Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum". The investigators will compare the effectiveness of gabapentin to metoclopramide for 1 week among 60 women with hyperemesis gravidarum (HG) in this randomized, double-blinded trial. After completion of the 1-week double-blind phase, subjects will be offered open-label gabapentin with rescue metoclop...
What is the current status of trial NCT02163434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2014-06. Estimated completion is 2019-11.
What conditions does trial NCT02163434 study?
This clinical trial studies the following conditions: Hyperemesis Gravidarum.
What interventions are being tested in trial NCT02163434?
The interventions under investigation include: Gabapentin (DRUG), Metoclopramide (DRUG).
Who is sponsoring clinical trial NCT02163434?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02163434 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02163434's enrollment target sits among peer trials
31 1578th of 2000 higher than 419 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia